Windlas Biotech (India) Today
| WINDLAS Stock | 945.50 1.45 0.15% |
PerformanceWeakest
| Odds Of DistressLow
|
Windlas Biotech is selling for under 945.50 as of the 1st of November 2025; that is 0.15 percent decrease since the beginning of the trading day. The stock's lowest day price was 936.6. Windlas Biotech has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 3rd of August 2025 and ending today, the 1st of November 2025. Click here to learn more.
Moving against Windlas Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Windlas Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Windlas Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Windlas Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President Marketing | Mohammed Aslam |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) |
Windlas Biotech Limited (WINDLAS) is traded on National Stock Exchange of India in India and employs 1,346 people. Windlas Biotech is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 19.89 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Windlas Biotech's market, we take the total number of its shares issued and multiply it by Windlas Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Windlas Biotech operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 21.08 M outstanding shares.
Windlas Biotech generates positive cash flow from operations, but has no cash available
Check Windlas Biotech Probability Of Bankruptcy
Ownership AllocationWindlas Biotech Limited retains a total of 21.08 Million outstanding shares. Windlas Biotech maintains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.36 (%) of Windlas Biotech outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Windlas Ownership Details
Windlas Biotech Risk Profiles
Although Windlas Biotech's alpha and beta are two of the key measurements used to evaluate Windlas Biotech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.27 | |||
| Standard Deviation | 2.11 | |||
| Variance | 4.43 | |||
| Risk Adjusted Performance | (0.01) |
Windlas Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Windlas Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Windlas Biotech Corporate Directors
| Ashok Windlass | WholeTime Director | Profile | |
| Manoj Windlass | Joint Director | Profile | |
| Hitesh Windlass | MD Director | Profile | |
| Pawan Sharma | Executive Director | Profile |
Additional Tools for Windlas Stock Analysis
When running Windlas Biotech's price analysis, check to measure Windlas Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windlas Biotech is operating at the current time. Most of Windlas Biotech's value examination focuses on studying past and present price action to predict the probability of Windlas Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windlas Biotech's price. Additionally, you may evaluate how the addition of Windlas Biotech to your portfolios can decrease your overall portfolio volatility.